Because these two processes are tightly correlated and because their crosstalk is heavily shaped by the Bcl-2:beclin-1 complex, therapeutic reprogramming aims to reshape this balance in a direction that disadvantages tumour survival. Here, BCL2 is linked to neoplasm.